Welcome to our dedicated page for Valneva Se SEC filings (Ticker: VALN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Valneva SE (VALN) is a French specialty vaccine company that reports to the U.S. Securities and Exchange Commission as a foreign private issuer. Its SEC filings, primarily on Form 20-F and Form 6-K, provide detailed insight into the company’s vaccine portfolio, segment reporting, financing arrangements and material agreements.
Through these filings, investors can review Valneva’s segment information, which distinguishes between Commercialized vaccines (including IXIARO/JESPECT, DUKORAL and IXCHIQ), Covid activities, Vaccine candidates and Technologies and services. Interim condensed consolidated financial statements filed on Form 6-K include revenue breakdowns by product groups, geographies and revenue types such as product sales, royalties, shipping and handling, milestone payments and other product-related income.
Valneva’s SEC reports also disclose key collaboration and financing structures. Examples include the amended collaboration and license agreement with Pfizer for the Lyme disease vaccine candidate VLA15, strategic partnership agreements related to chikungunya vaccine IXCHIQ, and loan agreements providing senior term loan facilities to refinance prior credit arrangements and fund general corporate and working capital requirements. These documents outline covenants, security interests over assets and intellectual property, and the role of subsidiaries that guarantee the company’s obligations.
On this page, Stock Titan surfaces Valneva’s latest SEC submissions as they are posted to EDGAR, including current reports on Form 6-K that furnish press releases, financial statements and business updates. AI-powered summaries help explain the key points of lengthy filings, such as changes in debt financing, updates to collaboration terms, or new clinical and regulatory disclosures. Users can quickly identify items related to vaccine segment performance, major agreements, and risk factor discussions without reading every page.
In addition to financial and operational information, Valneva’s filings may reference research tax credit arrangements, strategic partnerships with organizations such as the Coalition for Epidemic Preparedness Innovations (CEPI), and the structure of its international subsidiaries. This SEC filings page is designed to make those disclosures easier to navigate, with real-time updates and AI-generated highlights that point to the most relevant sections for vaccine-focused investors.
Valneva SE filed a Form 6-K report on June 28, 2025, indicating the issuance of a press release dated June 26, 2025. The filing was signed by CEO and President Thomas Lingelbach.
This Form 6-K submission serves primarily as a notification of foreign issuer disclosure, with the company confirming it files annual reports under Form 20-F. The press release content (Exhibit 99.1) is referenced but not detailed in the main filing.
Notably, the information contained in this Form 6-K, including Exhibit 99.1, has been incorporated by reference into the company's Registration Statement on Form F-3 (File No. 333-286071), which could indicate potential future securities offerings or other significant corporate actions.
Valneva SE (VALN) filed a routine Form 6-K with the U.S. SEC on 25 June 2025. The submission simply furnishes a company press release dated the same day as Exhibit 99.1 and explicitly incorporates that release into Valneva’s effective shelf Registration Statement on Form F-3 (File No. 333-286071). No financial statements, earnings figures, or transactional details accompany the filing. The document, signed by CEO and President Thomas Lingelbach, serves an administrative purpose—ensuring U.S. investors have access to the referenced press release within Valneva’s formal disclosure record.